The basis for the use of IVIG in SJS/TEN is via a combination of many pathways, including interfering with T cells, B cells, and monocytes which involve blocking the interaction of Fas with FasL (20–22). This evidence concerns the gene FASLG and Schwartz-Jampel syndrome.